Company research / IDXX

Idexx Laboratories Inc (IDXX)

SEC name IDEXX LABORATORIES INC /DE · CIK 0000874716 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Idexx Laboratories Inc reported revenue of $4.30B. Revenue grew 10.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $4.55B.

Key ratios (year ended 2025-12-31)

61.8%
Gross margin
31.6%
Operating margin
24.6%
Net margin
66.0%
Return on year-end equity
10.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-09

Headquarters locality: Westbrook · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 2-for-1, first reflected in a filing dated 2015-07-30. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$4.55B$4.30B$3.90B$3.66B$3.37B$3.22B$2.71B$2.41B$2.21B$1.97B$1.78B
Cost of Revenue$1.71B$1.64B$1.52B$1.47B$1.36B$1.33B$1.14B$1.04B$971.70M$871.68M$799.99M
Gross Profit$2.84B$2.66B$2.38B$2.19B$2.00B$1.89B$1.57B$1.37B$1.24B$1.10B$975.44M
R&D Expense$261.46M$251.21M$219.79M$190.95M$254.82M$161.01M$141.25M$133.19M$117.86M$109.18M$101.12M
Operating Income$1.46B$1.36B$1.13B$1.10B$898.76M$932.03M$694.52M$552.85M$491.33M$413.03M$350.24M
Depreciation & Amortization$154.08M$145.18M$129.94M$114.91M$111.90M$104.60M$96.00M$88.01M$83.18M$83.14M$78.22M
EBITDA$1.61B$1.51B$1.26B$1.21B$1.01B$1.04B$790.52M$640.86M$574.51M$496.17M$428.46M
Net Income$1.14B$1.06B$887.87M$845.04M$679.09M$744.85M$581.78M$427.72M$377.03M$263.14M$222.04M
EPS (Diluted)n/a$13.08$10.67$10.06$8.03$8.60$6.71$4.89$4.26$2.94$2.44
Total Assets$3.44B$3.35B$3.29B$3.26B$2.75B$2.44B$2.29B$1.83B$1.54B$1.71B$1.53B
Total Liabilities$1.83B$1.75B$1.70B$1.78B$2.14B$1.75B$1.66B$1.65B$1.55B$1.77B$1.64B
Long-Term Debtn/a$450.00M$617.80M$698.19M$769.77M$850.71M$909.10M$699.40M$601.80M$606.60M$593.70M
Shareholders' Equity$1.61B$1.61B$1.60B$1.48B$608.74M$689.99M$632.09M$177.47M-$9.51M-$54.11M-$108.35M
Cash & Equivalents$196.93M$180.07M$288.27M$453.93M$112.55M$144.45M$383.93M$90.33M$123.79M$187.68M$154.90M
Operating Cash Flow$1.37B$1.18B$929.00M$906.51M$542.98M$755.55M$648.06M$459.16M$400.08M$373.28M$338.94M
Capital Expenditures$117.18M$124.68M$120.92M$133.63M$148.84M$119.55M$106.96M$154.97M$115.75M$74.38M$64.79M
Free Cash Flow$1.25B$1.06B$808.08M$772.88M$394.15M$636.00M$541.11M$304.19M$284.33M$298.89M$274.16M
Share Repurchases$1.18B$1.22B$837.03M$71.92M$819.71M$746.78M$182.81M$301.66M$369.32M$282.56M$304.09M
Shares Outstanding78.87M79.71M81.60M83.03M82.89M84.56M85.45M85.47M86.10M87.10Mn/a
Weighted Average Diluted Sharesn/a81.03M83.25M83.98M84.60M86.57M86.72M87.54M88.47M89.57M90.88M
EPS (Basic)n/a$13.17$10.77$10.17$8.12$8.74$6.82$4.97$4.34$3.00$2.47

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView